Promising approaches are for example the combinations of Src-inhibitor dasatinib with EGFR-inhibitor afatinib in TNBC [65] or DDR1-inhibitor 7rh in nasopharyngeal carcinoma [45]. Here, EGFR is linked to nasopharyngeal carcinoma.